Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-04-18

FDA Approved: ABACAVIR AND LAMIVUDINE — Supplemental Application (Aurobindo Pharma Limited)

View source ↗

Summary

The FDA approved a supplemental application for Abacavir/lamivudine from Aurobindo Pharma Limited, enabling the marketing of this generic fixed-dose combination…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • abacavir/lamivudine (abacavir/lamivudine)

Snippet

SUPPL AP for ABACAVIR AND LAMIVUDINE (ABACAVIR AND LAMIVUDINE)